|
⚲
|
| Keyboard |
| Avoro Capital Advisors LLC
✚
|
|
|---|---|
| CRD # | 154091 |
| SEC # | 801-74391 |
| CIK # | 0001633313 |
| AUM | 13.55 B (2026-03-05) |
| Employees | 19 (58% Investors, 0% Brokers) |
| Phone | 212-937-4970 |
| Address | 110 Greene Street New York, NY 10012 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| United Therapeutics Corp | 1.8 | ||
| Ascendis Pharma A/S | 1.2 | ||
| Synta Pharmaceuticals Corp | 1.0 | ||
| Krystal Biotech Inc | 0.7 | ||
| Argenx SE | 0.7 | ||
| Arrowhead Research Corp | 0.7 | ||
| Kymera Therapeutics Inc | 0.6 | ||
| Celcuity Inc | 0.4 | ||
| Xenon Pharmaceuticals Inc | 0.3 | ||
| Structure Therapeutics Inc | 0.3 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Avoro Ventures Fund LP | [2021-03-23] | 178.4 M | 153.5 M |
| Filed 2021-07-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | venBio Global Strategic Fund II LP | [2016-03-29] | 337.0 M | 315.2 M |
| Offered $337,000,000 · Filed 2017-03-02 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration More than one year · Revenue Decline to Disclose | ||||
| HF | Avoro Life Sciences Fund LLC | [2012-02-22] | 2,110.0 M | 13.40 B |
| Filed 2025-05-02 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Commission $53,273,519 · Net Assets Decline to Disclose | ||||
| VC | venBio Global Strategic Fund LP | [2012-02-22] | 177.0 M | 178.8 M |
| Offered $237,000,000 · Filed 2013-10-29 (D/A) · Exemption 506(b) · Remaining $60,000,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 13.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 13.6 |
| By Discretionary | ||
| Discretionary | 3 | 13.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 13.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 5.9 | |
| United States Persons | 7.7 | |
| Total | 3 | 13.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Corey Goodman | Director, Executive Officer | 38 | 3 | |
| Robert Adelman | Director, Executive Officer | 23 | 3 | |
| Kurt von Emster | Director, Executive Officer | 20 | 3 | |
| Neil Cammarosano | Executive Officer | 7 | 3 | |
| Paul Brooke | Director, Executive Officer | 9 | 2 | |
| Behzad Aghazadeh | Executive Officer | 7 | 2 | |
| Scott Epstein | Executive Officer | 5 | 2 | |
| Avoro Capital LP | Promoter | 4 | 2 | |
| Avoro Capital GP LLC | Promoter | 4 | 2 | |
| Avoro Ventures LLC | Promoter | 2 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001633313] | |
| 3 | [0001633313] | |
| 4 | [0001633313] | |
| SC 13D | [0001633313] | |
| SC 13G | [0001633313] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.2B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Avoro Ventures LLC | |
| Aghazadeh Behzad | |
| Avoro Capital Advisors LLC | |
| Zeta Acquisition Corp II | |
| CymaBay Therapeutics Inc | |
| Immunomedics Inc | |
| Mirati Therapeutics Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Zeta Acquisition Corp II WHWK
Stock Option (right to buy) · derivative
|
2025-06-12 | Grant | 40,006 | $0.00 | |
|
Zeta Acquisition Corp II AADI
Pre-funded Warrant (right to buy) · derivative
|
2025-02-28 | Grant | 8,333,000 | $2.40 | 19,999,200 |
|
Zeta Acquisition Corp II AADI
Stock Option (right to buy) · derivative
|
2024-06-12 | Grant | 45,832 | $0.00 | |
|
CymaBay Therapeutics Inc CBAY
Put Option (obligation to buy) · derivative
|
2023-09-13 | Sell | 250 | $0.98 | 245 |
|
CymaBay Therapeutics Inc CBAY
Put Option (obligation to buy) · derivative
|
2023-09-13 | Sell | 950 | $1.10 | 1,045 |
|
CymaBay Therapeutics Inc CBAY
Put Option (obligation to buy) · derivative
|
2023-09-12 | Sell | 300 | $1.00 | 300 |
|
CymaBay Therapeutics Inc CBAY
Pre-funded Warrant (right to buy) · derivative
|
2023-09-12 | Buy | 583,771 | $17.13 | 9,999,997 |
|
CymaBay Therapeutics Inc CBAY
Put Option (obligation to buy) · derivative
|
2023-09-12 | Sell | 1,500 | $1.00 | 1,500 |
|
Zeta Acquisition Corp II AADI
Stock Option (right to buy) · derivative
|
2023-06-15 | Grant | 28,255 | $0.00 | |
|
CymaBay Therapeutics Inc CBAY
Pre-funded Warrant (right to buy) · derivative
|
2023-01-26 | Buy | 2,142,857 | $7.00 | 14,999,999 |
|
Zeta Acquisition Corp II AADI
"Common Stock, $0.0001 par value per share (""Common Stock"")"
|
2022-09-22 | Grant | 1,260,000 | $12.50 | 15,750,000 |
|
Zeta Acquisition Corp II AADI
Stock Option (right to buy) · derivative
|
2022-06-15 | Grant | 18,573 | $0.00 | |
|
CymaBay Therapeutics Inc CBAY
Pre-funded Warrant (right to buy) · derivative
|
2021-11-22 | Buy | 2,500,000 | $4.00 | 10,000,000 |
|
Zeta Acquisition Corp II AADI
Stock option (right to buy) · derivative
|
2021-08-27 | Grant | 17,549 | $0.00 | |
|
Zeta Acquisition Corp II AADI
"Common Stock, $0.0001 par value per share (""Common Stock"")"
|
2021-08-26 | Grant | 1,911,752 | $13.08 | 25,005,716 |
|
Immunomedics Inc IMMU
Restricted Stock Unit · derivative
|
2020-10-23 | Disposed to issuer | 103,718 | ||
|
Immunomedics Inc IMMU
Common Stock
|
2020-10-23 | Disposed to issuer | 26,250,000 | ||
|
Immunomedics Inc IMMU
Common Stock
|
2020-10-23 | Disposed to issuer | 13,516 | ||
|
Immunomedics Inc IMMU
Stock Option (Right to Buy) · derivative
|
2020-10-23 | Disposed to issuer | 202,614 | ||
|
Immunomedics Inc IMMU
Common Stock, $0.01 par value per share (''Common Stock'')
|
2020-06-18 | Grant | 3,718 | $0.00 | |
| showing 20 of 71 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
BSP NY LLC
✚
|
NY | 14.24 B |
|
RTW Investments LP
✚
|
NY | 14.14 B |
|
SRS Investment Management LLC
✚
|
NY | 13.92 B |
|
Dynasty Wealth Management LLC
✚
|
FL | 13.88 B |
|
LibreMax Capital LLC
✚
|
NY | 13.87 B |
|
Eagle Point Credit Management LLC
✚
|
CT | 13.24 B |
|
Post Advisory Group LLC
✚
|
CA | 13.03 B |
|
Ivy Hill Asset Management LP
✚
|
NY | 12.96 B |
|
Lingotto Investment Management LLP
✚
|
12.71 B | |
|
First Eagle Alternative Credit LLC
✚
|
MA | 12.56 B |